Sarepta Therapeutics, Inc. develops and commercializes precision genetic medicines for rare diseases, with a central focus on Duchenne muscular dystrophy and other neuromuscular conditions. Company news commonly covers product revenue and commercialization trends for ELEVIDYS and PMO therapies, including AMONDYS 45, VYONDYS 53 and EXONDYS 51.
Updates also address FDA interactions for Duchenne therapies, clinical and biomarker data from the siRNA pipeline, and programs such as SRP-1001 for FSHD1 and SRP-1003 for DM1. Other recurring announcements include quarterly financial results, Nasdaq inducement equity grants, and patient-community initiatives tied to Duchenne muscular dystrophy.
Sarepta Therapeutics (NASDAQ:SRPT) reported third-quarter 2026 revenue of $381.4 million, down 5% from the same period a year earlier. Net product revenue was approximately $323.8 million, including approximately $240.3 million from PMO products and $83.5 million from ELEVIDYS. GAAP operating loss narrowed to $9.0 million from $103.4 million; non-GAAP operating income reached $22.9 million.
The company raised its 2026 net product revenue guidance floor by $50.0 million to $1.25 billion–$1.3 billion and lowered its combined non-GAAP research and administrative expense ceiling by $25.0 million to $800 million–$825 million. Cash, restricted cash and investments totaled $998.7 million. Sarepta expects multiple-dose data for SRP-1003 in DM1 and SRP-1001 in FSHD in the fourth quarter and is preparing both programs for potential Phase 3 development.
Sarepta Therapeutics (NASDAQ:SRPT) announced that senior management will participate in two investor conferences on Nov. 9, 2026.
The events are the Wolfe Research Healthcare Conference in New York City and Guggenheim Securities Healthcare Innovation Conference in Boston. The Guggenheim fireside chat is scheduled for 3 p.m. ET, with a live webcast on Sarepta’s investor relations website and an archive available for 90 days afterward.
Sarepta Therapeutics (SRPT) will report third quarter 2026 financial results after the Nasdaq Global Market closes on Nov. 5, 2026.
A conference call to discuss the results will follow at 4:30 p.m. ET. A live webcast will be available on Sarepta's investor relations website, with a replay archived there for one year.
Sarepta Therapeutics (SRPT) presented preclinical data showing its investigational DM1 treatment SRP-1003 reduced disease-causing DMPK RNA within the cell nucleus.
In patient-derived muscle cells, SRP-1003 achieved up to approximately 80% reduction in DMPK RNA in both nuclear and cytoplasmic compartments, with dose-dependent effects. Nuclear activity was supported by three independent measurement methods. Treatment also reduced toxic nuclear RNA clusters in skeletal muscle, diaphragm and heart muscle in a DM1 mouse model. In a second mouse model, a surrogate siRNA reduced pathogenic nuclear DMPK RNA and corrected MBNL-dependent mis-splicing, an error in RNA processing, in a dose-dependent manner.
Separate preclinical studies detected SRP-1003 across multiple muscle groups for up to 16 weeks after one intravenous dose. Sarepta expects results from its ongoing Phase 1/2 study later in 2026.
Sarepta Therapeutics (SRPT) granted 211,070 restricted stock units as employment inducements to individuals hired in the third quarter of 2026.
The awards went to 37 employees on September 30, 2026, under the 2024 Employment Commencement Incentive Plan. The board’s Compensation Committee previously approved them in accordance with Nasdaq Listing Rule 5635(c)(4). Restricted stock units are equity awards that vest over time: one-fourth will vest on each grant-date anniversary, with full vesting on the fourth anniversary, subject to continued employment on each vesting date. Employees received no stock options.
Sarepta Therapeutics (SRPT) presented ELEVIDYS data showing functional benefits over two years in older ambulatory patients with Duchenne muscular dystrophy.
The analysis compared 25 patients treated at ages 8–12 with 99 matched external controls. Adjusted differences favored treatment by 3.32 points on the North Star Ambulatory Assessment, a motor-function scale, 0.041 rise/second for rising from the floor and 0.195 meters/second for the 10-meter walk/run. Differences were nominally statistically significant at Years 1 and 2.
In children aged 2 to under 3, mean protein expression at 12 weeks was 93.9% of control in ENDEAVOR and 72.8% in ENVOL, involving six and three patients, respectively. Functional follow-up continues. No new safety signals were identified in these analyses; nausea and vomiting were the most common treatment-related adverse events in older patients.
Sarepta Therapeutics (SRPT) will present Duchenne muscular dystrophy treatment data at the World Muscle Society congress beginning September 29.
A September 30 late-breaking poster will cover functional and safety outcomes for ambulatory patients who were aged 8–12 when treated with delandistrogene moxeparvovec. Other posters will cover up to three years of follow-up in the EMBARK study, micro-dystrophin expression in children aged 2–3, pooled safety data, and Phase 3 ESSENCE results for golodirsen and casimersen compared with placebo. The congress runs through October 3 in Hiroshima, Japan. ELEVIDYS, Sarepta’s delandistrogene moxeparvovec therapy, carries a boxed warning for acute serious liver injury and acute liver failure.
Sarepta Therapeutics (SRPT) will present seven neuromuscular research posters at the NMSG Scientific Meeting on September 25, 2026.
The program includes the first results from ENDURE, a Phase 4 observational study of patients receiving delandistrogene moxeparvovec for Duchenne muscular dystrophy. Its analyses include safety in patients who received preventive sirolimus. Other posters address treatment delays, postmarketing safety and mobility. Two posters cover interim safety and exposure findings from Phase 1/2 studies of SRP-1003 in myotonic dystrophy type 1 and SRP-1001 in FSHD1.
Sarepta Therapeutics (SRPT) announced 25 recipients of its Route 79, The Duchenne Scholarship Program for the 2026-2027 academic year.
The academic scholarships include 20 individuals living with Duchenne muscular dystrophy and five siblings of individuals living with Duchenne, each eligible for up to $5,000. Now in its ninth year, the program has awarded more than 150 scholarships to support postsecondary education. Recipients are selected by an independent committee of Duchenne community members based on academic record, community involvement, personal essay and recommendation letter, with applications de-identified regarding past or planned Sarepta therapies.
Sarepta Therapeutics (NASDAQ:SRPT) announced that senior management will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, Sept. 14, at 8:30 a.m. ET. The presentation will be webcast live and available in the investor relations section of Sarepta’s website, where it will be archived for 90 days.